Skip To Main Content
Lilly
Menu closed
Lilly
  • Medical Home
  • Medical Education
      • All Therapeutic Areas
        • Alopecia Areata
        • Atopic Dermatitis
        • Psoriasis
        • Diabetes
        • Hypoglycemia
        • Inflammatory Bowel Disease
        • Ulcerative Colitis
        • COVID-19
        • Headache Disorders
        • Neurodegeneration
        • Breast Cancer
        • Hematologic Cancer
        • Axial Spondyloarthritis
        • Psoriatic Arthritis
        • Rheumatoid Arthritis
        • Resources
      • All Therapeutic Areas
        • Alopecia Areata
        • Atopic Dermatitis
        • Psoriasis
        • Diabetes
        • Hypoglycemia
        • Inflammatory Bowel Disease
        • Depression
        • Headache Disorders
        • Breast Cancer
        • Gastrointestinal Cancer
        • Oncology General
        • Osteoporosis
        • Rheumatoid Arthritis
        • Resources
  • Independent Medical Education
      • Alopecia Areata
      • Atopic Dermatitis
      • Psoriasis
    • Diabetes
      • Ulcerative Colitis
      • COVID-19
      • Headache Disorders
      • Neurodegeneration
    • Obesity
      • Breast Cancer
      • Gastrointestinal Cancer
      • Hematologic Cancer
      • Non-small Cell Lung Cancer
      • Prostate Cancer
      • Oncology General
      • Precision Medicine and Diagnostics
      • Axial Spondyloarthritis
      • Systemic Lupus Erythematosus
      • Psoriatic Arthritis
      • Rheumatoid Arthritis
  • Chat Contact Us

Disease Education Resources

Oncology

Please select your disease state of interest to explore medical education resources.

Breast Cancer

Identifying HR+,HER2- EBC Patients at a Higher Risk of Recurrence

Identifying HR+,HER2- EBC Patients at a Higher Risk of Recurrence

Learn about clinical & pathological features that may increase the risk of recurrence in patients with HR+,HER2- early breast cancer.

Program
Ki-67 as a Prognostic Factor for Recurrence in HR+/HER2- Early Breast Cancer

Ki-67 as a Prognostic Factor for Recurrence in HR+/HER2- Early Breast Cancer

A short educational series of videos & slides about Ki-67 as a prognostic factor for recurrence in patients with HR+/HER2- EBC

Program
Identifying Patients with HR+ HER2- Early Breast Cancer who are at a Higher Risk of Recurrence

~20% of patients with HR+/HER2- EBC may progress to metastatic disease, commonly within a few years after primary treatment. This slide deck provides details on the clinical & pathological factors that may affect the risk of recurrence in people with EBC.

Supporting Adherence and Persistence to Oral Medications in Patients with Breast Cancer

This slide deck is intended to educate Health Care Providers on factors that influence medication adherence/persistence, and provides tools, resources, and guidelines to help improve adherence for their patients.




Patient Education Resources

Explore our library of patient based education materials to aid in HCP to patient interactions.

Review patient resources
  • Copyright
  • Terms of Use
  • Privacy Statement
  • Accessibility Statement
  • Sitemap

To speak to customer support:
Call (XXX) XXX-XXXX

This site is intended for US Healthcare Professionals only.

4.1.3 01/2023 | GLOOTH00001 04/2015 | © Lilly USA, LLC 2023. All rights reserved.

Product names listed above are trademarks or registered trademarks owned by or licensed to Eli Lilly and Company, its subsidiaries, or affiliates

Facebook Twitter
Lilly